article
In this exclusive interview with Young Kwon, CEO of Alchemab,…
22 August 2023 | By Taylor Mixides (Drug Target Review)
In this exclusive interview with Young Kwon, CEO of Alchemab, we discuss new platforms that are revolutionising how researchers identify naturally occurring antibodies in resilient individuals, opening up new possibilities for the development of disease-modifying therapies.